4.6 Review

Kidney Disease: Improving Global Outcomes-an update

Journal

NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 29, Issue 4, Pages 763-769

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gft441

Keywords

controversies conferences; guidelines; implementation; KDIGO; methodology

Funding

  1. International Society of Nephrology
  2. Transplantation Society
  3. American Society of Nephrology
  4. Canadian Blood Services
  5. Canadian Society of Nephrology
  6. Abbott
  7. Amgen
  8. Bayer Schering Pharma
  9. Belo Foundation
  10. Bristol-Myers Squibb
  11. Chugai Pharmaceutical
  12. Coca-Cola Company
  13. Dole Food Company
  14. Fresenius Medical Care
  15. Genzyme
  16. Hoffmann-LaRoche
  17. JC Penney
  18. Kyowa Hakko Kirin
  19. NATCO-The Organization for Transplant Professionals
  20. NKF
  21. Novartis
  22. Pharmacosmos
  23. PUMC Pharmaceutical
  24. Robert and Jane Cizik Foundation
  25. Shire
  26. Takeda Pharmaceutical
  27. Transwestern Commercial Services
  28. Vifor Pharma
  29. Wyeth

Ask authors/readers for more resources

Kidney Disease: Improving Global Outcomes (KDIGO) was founded in 2003 to fulfill a need for international cooperation and consolidation in the development and implementation of clinical practice guidelines. KDIGO has experienced a rapid growth in the development of guidelines, producing three guidelines in its first 6 years and another six in the last 3 years. In addition, it has held 12 global conferences on important issues in kidney disease and its treatment. A major effort is under way to support the dissemination and implementation of KDIGO guidelines through various channels, including an Implementation Task Force with official representatives in 86 countries. KDIGO is now under its own management and remains committed to the development of evidence-based guidelines. Future challenges include finding adequate sources of funding and building stronger links with other organizations involved in guideline development and implementation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available